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1. Background 
Decision analytic models (DAM) in health care are generally used to assess different interventions to 
determine which provides the best value for money 
[1]
.  These models explore both the costs and the 
benefits accrued by patients receiving the interventions and results are presented in terms of the 
incremental cost per benefit of the intervention under evaluation 
[2]
.  Whilst not all policy decision 
makers and reimbursement authorities conform to the same methodology 
[3]
, there has been a 
substantial growth in the use of incremental cost per quality adjusted life year (QALY) over the last 
two decades 
[4]
.  As the incremental QALY is the denominator in the outputs of the model, results 
can be sensitive to both the health state utility values (HSUV) used and the methods and techniques 
used to deploy these values within the model 
[5]
. 
 
The different components or stages involved in sourcing appropriate HSUVs (Figure 1) are rarely 
independent and the process is generally iterative and often challenging 
[6]
.  In addition to identifying 
an appropriate preference-based measure for the particular condition (Figure 1), and satisfying any 
associated reimbursement agency requirements, factors such as: the advantages (or disadvantages) 
of collecting utility evidence in randomised clinical trials and other sources 
[7]
, the potential need to 
use a mapping function to predict the required HSUVs 
[8]
, and satisfying the exact and often evolving 
health states used within the DAM all require consideration. 
 
Once the most appropriate HSUVs available have been identified, these may not match the 
requirements of the DAM exactly and analysts may then need to make a series of methodological 
decisions or assumptions related to the practicalities of using this evidence within the DAM.  These 
may include adjustments to account for age, gender or adverse events, evidence for the baseline or 
counterfactual (i.e. the trajectory of HSUVs for people who do not have a particular health condition 
or clinical event), estimate HSUVs for comorbidities (when a second health condition is present 
concurrently with the primary health condition), and characterising uncertainty appropriately (when 
using summary statistics sourced from different studies) (Figure 1). 
 
2. Existing recommendations on best practice 
2.1 Recommendations for decision analytic models 
Guidance on appropriate DAM approaches are available in the literature 
[1;2;9;10;11]
 and cover: the 
choice of model structure 
[12]
, measuring and estimating costs 
[13;14]
; identifying, reviewing and 
synthesising evidence on HRQoL 
[6;15]
,
 
and methods for characterising uncertainty
 [16]
.  In addition, a 
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number of checklist have been published over the years to encourage good practice in this area 
[1;2;9;17;18]
. 
 
It is worth noting that there are issues where best practice can be defined and issues for which 
countries may have legitimately different preferences (such as the use of public or patient 
preferences).  Both the US Panel on Cost-effectiveness in Health and Medicine, and the UK National 
Institute for Health and Care Excellence (NICE) have developed guides with a view to standardising 
the methodological approaches in health technology appraisals to facilitate comparability of 
submissions 
[19;20]
.  However, these and similar guidelines in other settings do not provide detailed 
guidance on good practice for HSUVs other than stating a preference for a particular preference-
based measure (e.g. EQ-5D), source of evidence (e.g. patient), methodology (e.g. time trade-off) and 
source of preference-weights (e.g. general population or patient), or specifying a specific output 
form the models (e.g. cost per QALY).   
 
2.2 Recommendations for health state utility values 
A series of technical support documents commissŝŽŶĞĚǀŝĂE/ ?ƐĞĐŝƐŝŽŶ^ƵƉƉŽƌƚhŶŝƚŝŶ ? ? ? ?
provide some recommendations of good practice when using HSUVs 
[6;21;22;23]
 and a recent textbook 
provides an up to date review of preference-based measures of health 
[24]
. 
 
More recently, their use 
in DAMs has formed the focus of two ISPOR task force reports 
[7;8]
.  The first describes a framework 
for collecting HSUVs within clinical studies and covers a broad spectrum from early planning of 
requirements, inclusion in clinical trial protocols, the advantages and design of alternative sources 
such as prospective and cross-sectional observational studies, statistical analyses and reporting 
standards 
[7]
.  The second provides recommendations relating to conducting high quality mapping 
studies involving HSUVs and includes: good practices for the selection of datasets used to obtain the 
mapping function, model selection and performance assessment, the use of results (including 
characterising variability and uncertainty appropriately), and reporting standards 
[8]
. 
 
3. Standardising good practices 
Good practice recommendations and checklists have evolved over time to address the 
developments in methodological research and the needs associated with the increasing complexity 
of DAMs.  Consequently there is no common source that covers the state of the art 
recommendations across the full spectrum of considerations associated with the use of HSUVs 
informing DAMs and there are still areas where recommendations for good practice are absent.  The 
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result of this is there is no standardisation across current practice and policy decisions informed by 
the results from these models may be suboptimal.  
 
The articles in this special issue provide a comprehensive compilation of the most robust 
recommendations in this area and are intended as a reference source for state of the art evidence 
on good practice across the full spectrum of needs associated with HSUVs that inform DAMs. 
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Figure 1: The iterative process involved in identifying, analysing and using health state utility values used in decision analytic models 
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